MA52967B1 - Composés antagonistes du pcsk9 - Google Patents

Composés antagonistes du pcsk9

Info

Publication number
MA52967B1
MA52967B1 MA52967A MA52967A MA52967B1 MA 52967 B1 MA52967 B1 MA 52967B1 MA 52967 A MA52967 A MA 52967A MA 52967 A MA52967 A MA 52967A MA 52967 B1 MA52967 B1 MA 52967B1
Authority
MA
Morocco
Prior art keywords
compounds
antagonist compounds
pcsk9 antagonist
pcsk9
formula
Prior art date
Application number
MA52967A
Other languages
English (en)
Other versions
MA52967A (fr
Inventor
Fa-Xiang Ding
Chengwei WU
Elisabetta Bianchi
Harold B. Wood
Hubert B. Josien
Thomas Joseph Tucker
Angela Dawn KEREKES
Ling Tong
Abbas M. Walji
Anilkumar G. NAIR
Danila Branca
Yusheng Xiong
Sookhee Nicole Ha
Jian Liu
Sobhana Babu Boga
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MA52967A publication Critical patent/MA52967A/fr
Publication of MA52967B1 publication Critical patent/MA52967B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des composés de formule I, ou un sel de ceux-ci, formule dans laquelle A, B, D, X, R1, R2 et R8 sont tels que définis dans la description, lesdits composés présentant des propriétés antagonistes au niveau du PCSK9. L'invention concerne également des formulations pharmaceutiques comprenant les composés de formule I ou leurs sels, et des procédés de traitement de maladies cardiovasculaires et d'états liés à l'activité du PCSK9, par exemple l'athérosclérose, l'hypercholestérolémie, la coronaropathie, le syndrome métabolique, le syndrome coronarien aigu ou les maladies cardiovasculaires et cardiométaboliques associées.
MA52967A 2018-06-21 2019-06-20 Composés antagonistes du pcsk9 MA52967B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687913P 2018-06-21 2018-06-21
PCT/US2019/038155 WO2019246349A1 (fr) 2018-06-21 2019-06-20 Composés antagonistes du pcsk9
EP19739801.9A EP3810626B1 (fr) 2018-06-21 2019-06-20 Composés antagonistes du pcsk9

Publications (2)

Publication Number Publication Date
MA52967A MA52967A (fr) 2021-04-28
MA52967B1 true MA52967B1 (fr) 2025-09-30

Family

ID=67263083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52967A MA52967B1 (fr) 2018-06-21 2019-06-20 Composés antagonistes du pcsk9

Country Status (38)

Country Link
US (3) US11427616B2 (fr)
EP (2) EP3810626B1 (fr)
JP (3) JP7112531B2 (fr)
KR (2) KR20250161677A (fr)
CN (2) CN121130044A (fr)
AR (1) AR115597A1 (fr)
AU (2) AU2019290163C1 (fr)
BR (1) BR112020025274A8 (fr)
CA (1) CA3102629A1 (fr)
CL (2) CL2020003257A1 (fr)
CO (1) CO2021000456A2 (fr)
CR (1) CR20210031A (fr)
DK (1) DK3810626T3 (fr)
DO (1) DOP2020000250A (fr)
EA (1) EA202190086A1 (fr)
EC (1) ECSP21003643A (fr)
ES (1) ES3047399T3 (fr)
FI (1) FI3810626T3 (fr)
GE (2) GEP20237506B (fr)
HR (1) HRP20251302T1 (fr)
HU (1) HUE073367T2 (fr)
IL (2) IL321719A (fr)
JO (1) JOP20190150A1 (fr)
LT (1) LT3810626T (fr)
MA (1) MA52967B1 (fr)
MD (1) MD3810626T2 (fr)
MX (1) MX2020013726A (fr)
NI (1) NI202000101A (fr)
PE (1) PE20211584A1 (fr)
PH (1) PH12020552187A1 (fr)
PL (1) PL3810626T3 (fr)
PT (1) PT3810626T (fr)
RS (1) RS67338B1 (fr)
SG (1) SG11202012451WA (fr)
SI (1) SI3810626T1 (fr)
TW (1) TWI840376B (fr)
UA (1) UA129467C2 (fr)
WO (1) WO2019246349A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100558932B1 (ko) * 2005-04-21 2006-03-10 주식회사 엠제이스마트 테크놀러지 다공성 세라믹 분리막 제조방법과, 이에 의해 제조되어진 다공성 세라믹 분리막
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
AU2015258863B2 (en) 2014-05-16 2019-10-24 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3749345A4 (fr) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. Mimétiques d'hepcidine conjugués
IL321719A (en) 2018-06-21 2025-08-01 Merck Sharp ַ& Dohme Llc Pcsk9 antagonist compounds
WO2019246386A1 (fr) 2018-06-21 2019-12-26 Ra Pharmaceuticals Inc. Polypeptides cycliques pour l'inhibition de la pcsk9
WO2019246352A1 (fr) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Composés bicycliques antagonistes de pcsk9
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
EP3810177B1 (fr) 2018-06-21 2024-12-04 Ra Pharmaceuticals, Inc. Peptides cycliques pour l'inhibition de la pcsk9
US11505575B2 (en) 2018-06-21 2022-11-22 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
WO2021041770A1 (fr) * 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Composés antagonistes du pcsk9
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
CN118063554A (zh) 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
TW202330013A (zh) 2021-07-14 2023-08-01 美商健生生物科技公司 介白素－２３受體之脂化肽抑制劑
MX2024002146A (es) 2021-08-19 2024-03-08 Merck Sharp & Dohme Llc Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9.
EP4540267B1 (fr) 2022-06-15 2026-04-15 Merck Sharp & Dohme LLC Peptides cycliques pour piéger l'interleukine-1 bêta
CN119731194A (zh) * 2022-08-17 2025-03-28 默沙东有限责任公司 Pcsk9抑制剂的结晶形式、组合物及用途
EP4727552A2 (fr) * 2023-06-15 2026-04-22 Merck Sharp & Dohme LLC Composés antagonistes de pcsk9 perméables passifs
US20250152658A1 (en) 2023-11-14 2025-05-15 Merck Sharp & Dohme Llc Cyclic peptide for trapping interleukin-1 beta
WO2025128805A1 (fr) 2023-12-15 2025-06-19 Merck Sharp & Dohme Llc Piège à il-1 bêta à peptide cyclique pour le traitement de l'athérosclérose et de troubles inflammatoires
WO2025242221A1 (fr) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 Nouvelle chaîne latérale modifiée, son procédé de préparation et son utilisation
WO2025264781A1 (fr) * 2024-06-18 2025-12-26 Kemira Oy J Agents de cationisation pour saccharides et procédés
WO2026019624A1 (fr) * 2024-07-15 2026-01-22 Merck Sharp & Dohme Llc Synthèse d'oligopeptides cycliques
WO2026019622A1 (fr) * 2024-07-15 2026-01-22 Merck Sharp & Dohme Llc Formes cristallines d'un cyclictétrapeptide et procédés de préparation
WO2026032253A1 (fr) * 2024-08-06 2026-02-12 石药集团中奇制药技术（石家庄）有限公司 Analogue de peptide cyclique, son procédé de préparation et son utilisation
WO2026034639A1 (fr) * 2024-08-09 2026-02-12 株式会社Spin Wave Excipient soluble pour la synthèse de peptides et procédé de synthèse l'utilisant
CN119930471A (zh) * 2024-12-31 2025-05-06 苏州默迪夫生物科技有限公司 Mk-a的制备方法、所用的中间体及其合成方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393046A (en) 1981-01-30 1983-07-12 Merck & Co., Inc. Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency
US4656269A (en) 1986-04-15 1987-04-07 Kissei Pharmaceutical Co., Ltd. Histidine derivatives
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
ZA981936B (en) 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
WO1998039342A1 (fr) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes d'indole et d'azaindole inhibiteurs de fructose-1,6-biophosphatase
WO1998039344A1 (fr) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
WO2000014095A1 (fr) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Nouveaux inhibiteurs heteroaromatiques de fructose-1,6-biphosphatase
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
NZ538031A (en) 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
JP4340232B2 (ja) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
WO2004066963A2 (fr) 2003-01-17 2004-08-12 Merck & Co., Inc. Derives de n-cyclohexylaminocarbonyl benzenesulfonamide
WO2008057459A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
CA2691010A1 (fr) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Pyrimidines fusionnees substituees en tant qu'antagonistes de l'activite de gpr105
EP2174343A1 (fr) 2007-06-28 2010-04-14 Semiconductor Energy Laboratory Co, Ltd. Procédé de fabrication d'un dispositif à semi-conducteurs
WO2009042053A2 (fr) 2007-09-21 2009-04-02 Merck & Co., Inc. Agonistes du récepteur de la neuromédine u et leurs utilisations
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
WO2009148605A2 (fr) 2008-06-04 2009-12-10 Isis Pharmaceuticals, Inc. Procédés pour traiter une hypercholestérolémie
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011037791A1 (fr) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonistes de pcsk9
CA2813049A1 (fr) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Compstatine modifiee ayant des proprietes de stabilite et de liaison ameliorees
KR101510975B1 (ko) 2010-12-28 2015-04-10 카딜라 핼쓰캐어 리미티드 이상지질혈증의 치료에 적절한 헤테로시클릭 화합물
KR20140006022A (ko) * 2011-02-11 2014-01-15 아이알엠 엘엘씨 Pcsk9 길항제
WO2012131504A1 (fr) 2011-03-02 2012-10-04 Pfizer Inc. Vaccin à base de pcsk9
WO2012168491A1 (fr) * 2011-06-10 2012-12-13 Novartis Ag Formulations pharmaceutiques d'antagonistes de pcsk9
KR20140041747A (ko) 2011-06-20 2014-04-04 제넨테크, 인크. Pcsk9-결합 폴리펩티드 및 사용 방법
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
KR20150000461A (ko) 2011-10-27 2015-01-02 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
EP2850095B1 (fr) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Inhibiteurs peptidiques et peptidomimétiques
EP2684865A1 (fr) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Procédés de synthèse de bloc de construction dýamatoxine et amatoxine
SG11201505856TA (en) 2013-03-14 2015-08-28 Daiichi Sankyo Co Ltd Novel binding proteins for pcsk9
JP2016512825A (ja) 2013-03-15 2016-05-09 シファ・バイオメディカル・コーポレイションＳｈｉｆａ Ｂｉｏｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 抗プロタンパク質転換酵素サブチリシン／ケキシン９型（抗ｐｃｓｋ９）化合物および心血管疾患の治療および／または予防におけるその使用方法
ES2914978T3 (es) 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
HUE045646T2 (hu) 2014-06-12 2020-01-28 Ra Pharmaceuticals Inc Komplement aktivitás modulálása
US10557129B2 (en) 2015-01-30 2020-02-11 Pronasci Inc. Peptides derived from human PCSK9 catalytic domain and uses thereof for promoting LDL-R activity
MY195199A (en) 2016-01-13 2023-01-11 Novo Nordisk As EGF(A) Analogues with Fatty Acid Substituents
CN107286158A (zh) 2016-03-30 2017-10-24 中国科学院上海药物研究所 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用
EP3442991A4 (fr) 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. Peptides de liaison à ras et méthodes d'utilisation
CA3026823A1 (fr) 2016-06-24 2017-12-28 F. Hoffmann-La Roche Ag Compositions et methodes de traitement de maladie cardiovasculaire
US10577357B2 (en) 2016-09-19 2020-03-03 The Texas A&M University System Inhibitors of LDLR-PCSK9 protein-protein interaction and methods of their use
US11977968B2 (en) 2017-04-20 2024-05-07 Shanghai Cambricon Information Technology Co., Ltd. Sparse processing in neural network processors
CN107158002B (zh) * 2017-07-01 2020-06-16 维亚生物科技(上海)有限公司 苄撑巴比妥类化合物在作为pcsk9拮抗剂和降低低密度脂蛋白中的应用
EP3810177B1 (fr) 2018-06-21 2024-12-04 Ra Pharmaceuticals, Inc. Peptides cycliques pour l'inhibition de la pcsk9
WO2019246352A1 (fr) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Composés bicycliques antagonistes de pcsk9
WO2019246386A1 (fr) 2018-06-21 2019-12-26 Ra Pharmaceuticals Inc. Polypeptides cycliques pour l'inhibition de la pcsk9
US11505575B2 (en) 2018-06-21 2022-11-22 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
IL321719A (en) 2018-06-21 2025-08-01 Merck Sharp ַ& Dohme Llc Pcsk9 antagonist compounds
WO2021041770A1 (fr) 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Composés antagonistes du pcsk9
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds

Also Published As

Publication number Publication date
JP7112531B2 (ja) 2022-08-03
SI3810626T1 (sl) 2025-12-31
BR112020025274A8 (pt) 2023-02-14
JP2022141879A (ja) 2022-09-29
DOP2020000250A (es) 2021-02-28
US20230159592A1 (en) 2023-05-25
AU2022259744B2 (en) 2024-07-11
MD3810626T2 (ro) 2025-12-31
GEAP202215540A (en) 2022-12-12
JP7855670B2 (ja) 2026-05-08
NI202000101A (es) 2021-05-28
FI3810626T3 (fi) 2025-10-21
US20190389909A1 (en) 2019-12-26
US20250206781A1 (en) 2025-06-26
EP3810626B1 (fr) 2025-07-23
SG11202012451WA (en) 2021-01-28
CL2020003257A1 (es) 2021-07-23
AR115597A1 (es) 2021-02-03
IL321719A (en) 2025-08-01
KR102884527B1 (ko) 2025-11-13
ECSP21003643A (es) 2021-02-26
TW202019950A (zh) 2020-06-01
BR112020025274A2 (pt) 2021-03-09
HRP20251302T1 (hr) 2025-12-19
LT3810626T (lt) 2025-11-10
AU2019290163C1 (en) 2022-11-03
KR20210024035A (ko) 2021-03-04
JP2025041712A (ja) 2025-03-26
PE20211584A1 (es) 2021-08-18
US11427616B2 (en) 2022-08-30
US12209145B2 (en) 2025-01-28
GEP20237506B (en) 2023-05-25
EA202190086A1 (ru) 2021-05-18
JOP20190150A1 (ar) 2019-12-21
UA129467C2 (uk) 2025-05-07
MX2020013726A (es) 2021-03-02
AU2022259744A1 (en) 2022-12-01
AU2019290163B2 (en) 2022-08-04
RS67338B1 (sr) 2025-11-28
EP3810626A1 (fr) 2021-04-28
EP4660303A3 (fr) 2026-02-25
CN112313243B (zh) 2025-09-02
IL279363B1 (en) 2025-08-01
EP4660303A2 (fr) 2025-12-10
DK3810626T3 (da) 2025-08-18
PH12020552187A1 (en) 2021-07-26
PT3810626T (pt) 2025-10-15
PL3810626T3 (pl) 2025-12-22
TWI840376B (zh) 2024-05-01
CN112313243A (zh) 2021-02-02
CO2021000456A2 (es) 2021-01-29
ES3047399T3 (en) 2025-12-03
WO2019246349A8 (fr) 2021-02-04
MA52967A (fr) 2021-04-28
CR20210031A (es) 2021-02-11
JP7607615B2 (ja) 2024-12-27
CL2022000027A1 (es) 2022-08-19
JP2021522311A (ja) 2021-08-30
AU2019290163A1 (en) 2021-01-07
HUE073367T2 (hu) 2026-01-28
WO2019246349A1 (fr) 2019-12-26
CA3102629A1 (fr) 2019-12-26
IL279363A (en) 2021-01-31
IL279363B2 (en) 2025-12-01
KR20250161677A (ko) 2025-11-17
CN121130044A (zh) 2025-12-16

Similar Documents

Publication Publication Date Title
PH12020552187A1 (en) Pcsk9 antagonist compounds
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
WO2016106331A8 (fr) Inhibiteurs d'idh1 mutants utiles pour traiter le cancer
MX380928B (es) Inhibidores de kras g12c.
EP2613782A4 (fr) Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012162254A8 (fr) Inhibiteurs de l'activité lrrk2 kinase
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
EP4631505A3 (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
HK1223917A1 (zh) 作为dyrk激酶抑制剂的2，3-二氢苯并呋喃-5-基化合物
NZ605444A (en) Salt and solvates of a tetrahydroisoquinoline derivative
MX376283B (es) Compuestos de imidazopiridazina.
EA201792072A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
ZA202108034B (en) Crystalline salt forms of a kinase inhibitor
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
WO2016165205A8 (fr) Nouvel inhibiteur de kinase bcr-abl
AR119864A1 (es) Compuestos antagonistas de pcsk9
WO2024259310A3 (fr) Composés antagonistes de pcsk9 perméables passifs
EA202190689A1 (ru) Производные хинолина в качестве ингибиторов интегрина альфа4бета7